|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase as a novel molecular target for cancer chemoprevention and therapy.
|
21856294 |
2011 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Concerted actions of ameliorated colitis, aberrant crypt foci inhibition and 15-hydroxyprostaglandin dehydrogenase induction by sonic hedgehog inhibitor led to prevention of colitis-associated cancer.
|
26476372 |
2016 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Use of a new tool, AHPT, in an in vitro model of peritoneal metastasis revealed that CR1 DNA inhibited cancer cell proliferation.
|
31025149 |
2019 |
|
Primary malignant neoplasm
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Altered expression of 15-hydroxyprostaglandin dehydrogenase in tumor-infiltrated CD11b myeloid cells: a mechanism for immune evasion in cancer.
|
19494278 |
2009 |
|
Colon Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer.
|
30931980 |
2019 |
|
Colon Carcinoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in 15-hydroxyprostaglandin dehydrogenase and colon cancer susceptibility.
|
23717544 |
2013 |
|
Colon Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
We also examined CBR1 inhibition by oleic acid in cellular levels: The fatty acid effectively inhibited CBR1-mediated 4-oxo-2-nonenal metabolism in colon cancer DLD1 cells and increased sensitivity to doxorubicin in the drug-resistant gastric cancer MKN45 cells that highly express CBR1.
|
28450226 |
2017 |
|
Colon Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
IHC showed CBR1 overexpression in 56 (72%) out of 78 HCC and 88 (72%) out of 123 colon cancer cases.
|
21056497 |
2011 |
|
Colon Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Anti-cancer Effects of MW-03, a Novel Indole Compound, by Inducing 15-Hydroxyprostaglandin Dehydrogenase and Cellular Growth Inhibition in the LS174T Human Colon Cancer Cell Line.
|
28966256 |
2017 |
|
Colorectal Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Effect of ginger root on cyclooxygenase-1 and 15-hydroxyprostaglandin dehydrogenase expression in colonic mucosa of humans at normal and increased risk for colorectal cancer.
|
23222413 |
2013 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Increased synthesis of PGE<sub>2</sub> in CRC has been shown to occur through COX-2-dependent mechanisms; however, loss of the PGE<sub>2</sub>-catabolizing enzyme, 15-hydroxyprostaglandin dehydrogenase (15-PGDH, HPGD), in colonic tumors contributes to increased prostaglandin levels and poor patient survival.
|
30931980 |
2019 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer.
|
19010907 |
2008 |
|
Colorectal Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer.
|
15542609 |
2005 |
|
Malignant neoplasm of lung
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Second, we detected 3.0-fold (p<0.0001) induction of CBR1 mRNA and 1.5-fold (p<0.01) induction of CBR1 protein levels in cells of the human lung cancer cell line A549 incubated with 2.5 μM B[a]P for 24h.
|
22531821 |
2012 |
|
Malignant neoplasm of lung
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
One SNP in CBR1 (rs2835267) was significantly associated with overall risk of lung cancer, but did not pass multiple testing adjustment (OR: 0.76 95% CI: 0.58-0.99, P = 0.048, FDR P = 0.20).
|
24976539 |
2015 |
|
Malignant neoplasm of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.
|
18593902 |
2008 |
|
Malignant neoplasm of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
A CBR framework with gradient boosting based feature selection for lung cancer subtype classification.
|
28527352 |
2017 |
|
Carcinoma of lung
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Second, we detected 3.0-fold (p<0.0001) induction of CBR1 mRNA and 1.5-fold (p<0.01) induction of CBR1 protein levels in cells of the human lung cancer cell line A549 incubated with 2.5 μM B[a]P for 24h.
|
22531821 |
2012 |
|
Carcinoma of lung
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
One SNP in CBR1 (rs2835267) was significantly associated with overall risk of lung cancer, but did not pass multiple testing adjustment (OR: 0.76 95% CI: 0.58-0.99, P = 0.048, FDR P = 0.20).
|
24976539 |
2015 |
|
Carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
A CBR framework with gradient boosting based feature selection for lung cancer subtype classification.
|
28527352 |
2017 |
|
Carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.
|
18593902 |
2008 |
|
Primary malignant neoplasm of lung
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Second, we detected 3.0-fold (p<0.0001) induction of CBR1 mRNA and 1.5-fold (p<0.01) induction of CBR1 protein levels in cells of the human lung cancer cell line A549 incubated with 2.5 μM B[a]P for 24h.
|
22531821 |
2012 |
|
Primary malignant neoplasm of lung
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
One SNP in CBR1 (rs2835267) was significantly associated with overall risk of lung cancer, but did not pass multiple testing adjustment (OR: 0.76 95% CI: 0.58-0.99, P = 0.048, FDR P = 0.20).
|
24976539 |
2015 |
|
Primary malignant neoplasm of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
A CBR framework with gradient boosting based feature selection for lung cancer subtype classification.
|
28527352 |
2017 |
|
Primary malignant neoplasm of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer.
|
18593902 |
2008 |